Advertisement

“BIClonals”: Production of Bispecific Antibodies in IgG Format in Transiently Transfected Mammalian Cells

  • Dana Litvak-Greenfeld
  • Lilach Vaks
  • Stav Dror
  • Limor Nahary
  • Itai BenharEmail author
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 1904)

Abstract

Bispecific antibodies (bsAbs) are antibodies with two binding sites directed at different antigens, enabling therapeutic strategies not possible with conventional monoclonal antibodies (mAbs). Since bispecific antibodies are regarded as promising therapeutic agents, many different bispecific design modalities have been evaluated. Many of these are based on antibody fragments or on inclusion of non-antibody components. For some therapeutic applications, full-size, native IgG-like bsAbs may be the optimal format.

To prepare bsAbs in IgG format, two challenges should be met. One is that each heavy chain will only pair with the heavy chain of the second specificity and that heavy chain homodimerization will be prevented. The second is that each heavy chain will only pair with the light chain of its own specificity and that pairing with the light chain of the second specificity will be prevented. The first solution to the first criterion (known as knobs into holes, KIH) was presented in 1996 by Genentech and additional solutions were presented more recently. However, until recently, out of >120 published formats, only a handful of solutions for the second criterion that make it possible to produce a bispecific IgG by a single expressing cell were suggested.

Here, we present a protocol for preparing bsAbs in IgG format in transfected mammalian cells. For heavy chain dimerization we use KIH while as a solution for the second challenge—correct pairing of heavy and light chains of bispecific IgGs we present our “BIClonals” technology; an engineered (artificial) disulfide bond between the antibodies’ variable domains that asymmetrically replaces the natural disulfide bond between CH1 and CL.

During our studies of bsAbs we found that H-L chain pairing seems to be driven by VH-VL interfacial interactions that differ between different antibodies; hence, there is no single optimal solution for effective and precise assembly of bispecific IgGs that suits every antibody sequence, making it necessary to carefully evaluate the optimal solution for each new antibody.

Key words

CDR Complementarity-determining region dsFv Disulfide-stabilized Fv fragment An IgG heavy chain KIH Knobs-into-holes An IgG light chain mAb Monoclonal antibody VH Variable domain of the heavy chain VL Variable domain of the light chain 

Notes

Acknowledgments

Studies of bispecific antibodies at the Authors’ lab were supported in part by The Israel Science Foundation (Grant no. 591/13), by a research grant from the Israel Cancer Research fund (ICRF), by a grant from the Israeli National Nanotechnology Initiative (INNI), Focal Technology Area (FTA) program: Nanomedicine for Personalized Theranostics, by The Leona M. and Harry B. Helmsley Nanotechnology Research Fund and by Varda and Boaz Dotan Research Center in Hemato-oncology affiliated to CBRC at Tel-Aviv University. We are grateful to members of the Benhar Lab for their contributions in optimizing the BIClonals technology.

References

  1. 1.
    Kaplon H, Reichert JM (2018) Antibodies to watch in 2018. mAbs 10:183–203CrossRefGoogle Scholar
  2. 2.
    Nelson AL, Dhimolea E, Reichert JM (2010) Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov 9:767–774CrossRefGoogle Scholar
  3. 3.
    Kontermann R (2012) Dual targeting strategies with bispecific antibodies. mAbs 4:182–197CrossRefGoogle Scholar
  4. 4.
    Riethmuller G (2012) Symmetry breaking: bispecific antibodies, the beginnings, and 50 years on. Cancer Immun 12:12–18PubMedPubMedCentralGoogle Scholar
  5. 5.
    Jost C, Plückthun A (2014) Engineered proteins with desired specificity: darpins, other alternative scaffolds and bispecific IgGs. Curr Opin Struct Biol 27C:102–112CrossRefGoogle Scholar
  6. 6.
    Krah S, Sellmann C, Rhiel L, Schroter C, Dickgiesser S, Beck J, Zielonka S, Toleikis L, Hock B, Kolmar H et al (2017) Engineering bispecific antibodies with defined chain pairing. N Biotechnol 39:167–173CrossRefGoogle Scholar
  7. 7.
    Brinkmann U, Kontermann RE (2017) The making of bispecific antibodies. mAbs 9:182–212CrossRefGoogle Scholar
  8. 8.
    Fischer N, Leger O (2007) Bispecific antibodies: molecules that enable novel therapeutic strategies. Pathobiology 74:3–14CrossRefGoogle Scholar
  9. 9.
    Rader C (2011) Darts take aim at bites. Blood 117:4403–4404CrossRefGoogle Scholar
  10. 10.
    Demarest SJ, Glaser SM (2008) Antibody therapeutics, antibody engineering, and the merits of protein stability. Curr Opin Drug Discov Devel 11:675–687PubMedGoogle Scholar
  11. 11.
    Dong J, Sereno A, Snyder WB, Miller BR, Tamraz S, Doern A, Favis M, Wu X, Tran H, Langley E et al (2011) Stable IgG-like bispecific antibodies directed toward the type I insulin-like growth factor receptor demonstrate enhanced ligand blockade and anti-tumor activity. J Biol Chem 286:4703–4717CrossRefGoogle Scholar
  12. 12.
    Klein C, Sustmann C, Thomas M, Stubenrauch K, Croasdale R, Schanzer J, Brinkmann U, Kettenberger H, Regula JT, Schaefer W (2012) Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies. mAbs 4:653–663CrossRefGoogle Scholar
  13. 13.
    Schaefer W, Regula JT, Bahner M, Schanzer J, Croasdale R, Durr H, Gassner C, Georges G, Kettenberger H, Imhof-Jung S et al (2011) Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc Natl Acad Sci U S A 108:11187–11192CrossRefGoogle Scholar
  14. 14.
    Merchant AM, Zhu Z, Yuan JQ, Goddard A, Adams CW, Presta LG, Carter P (1998) An efficient route to human bispecific IgG. Nat Biotechnol 16:677–681CrossRefGoogle Scholar
  15. 15.
    Lewis SM, Wu X, Pustilnik A, Sereno A, Huang F, Rick HL, Guntas G, Leaver-Fay A, Smith EM, Ho C et al (2014) Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface. Nat Biotechnol 32:191–198CrossRefGoogle Scholar
  16. 16.
    Benhar I, Vaks L. Bi- and monospecific, asymmetric antibodies and methods of generating the same. US patent number US 9,624,291 b2 issued Apr. 18, 2017. Priority date Mar. 15, 2012Google Scholar
  17. 17.
    Gibson DG, Young L, Chuang RY, Venter JC, Hutchison CA 3rd, Smith HO (2009) Enzymatic assembly of DNA molecules up to several hundred kilobases. Nat Methods 6:343–345CrossRefGoogle Scholar
  18. 18.
    Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680–685CrossRefGoogle Scholar
  19. 19.
    Kabat EA, Wu TT (1991) Identical V region amino acid sequences and segments of sequences in antibodies of different specificities. Relative contributions of VH and VL genes, minigenes, and complementarity-determining regions to binding of antibody-combining sites. J Immunol 147:1709–1719PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Dana Litvak-Greenfeld
    • 1
  • Lilach Vaks
    • 1
  • Stav Dror
    • 1
  • Limor Nahary
    • 1
  • Itai Benhar
    • 1
    Email author
  1. 1.School of Molecular Cell Biology and Biotechnology, The George S. Wise Faculty of Life SciencesTel-Aviv UniversityRamat AvivIsrael

Personalised recommendations